Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Comparing palifermin to ice chips in reducing oral inflammation in stem cell transplant patients
EF 2013-14
Résumé
A common treatment option for patients with cancers such as multiple myeloma and lymphoma is taking high-dose chemotherapy drugs followed by a stem cell transplant. However, some high-dose chemotherapy drugs, melphalan in particular, commonly cause severe side effects in patients. Mouth and throat inflammation and ulceration, called oral mucositis, is one of the most debilitating side effects; it can make eating and drinking extremely painful, patients are much more susceptible to infections and patients may need to be hospitalized for several weeks. Finding the best methods to help reduce the occurrence of oral mucositis will be beneficial for patients and for the healthcare system. Current treatment methods include giving patients a drug called palifermin intravenously before melphalan treatment or having patients place ice chips in their mouth before, during and after melphalan treatment. A small number of randomized controlled trials (RCTs) have compared these methods to placebo groups and found that the intervention, whether palifermin or ice chips, was more effective than the placebo under various specific conditions. However, to date, no RCT has compared palifermin to ice chips directly under equivalent and optimized conditions. Therefore, the current study aims to determine which treatment has greater ability to prevent incidence and duration of severe OM (grade 3 and 4 on the World Health Organization Oral Toxicity Scale) in stem cell transplant cancer patients undergoing melphalan chemotherapy. A total of 50 patients aged 18 or older of this described patient population will be randomized to receive either palifermin (25 patients) or ice chips (25 patients). In the palifermin group, patients will be administered the drug intravenously on the 3 days prior to melphalan treatment. In the ice chips group, patients will place ice chips in their mouth for 30 minutes prior to melphalan treatment and will continue until 2 hours after infusion. A trained assistant will physically examine and rate each patient’s mouth based on the Oral Toxicity Scale daily following intervention until patients are free of OM. Once measurements are complete, the proportion of patients with severe OM and the duration of severe OM will be calculated and compared between the groups. The ultimate goals will be to determine which intervention is more effective in reducing the incidence and duration of OM. The result of this study may have important implications for improving stem cell transplant patient quality of life and for optimizing healthcare expenditure.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
312003
Name
Suppiah Roopa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparing palifermin to ice chips in reducing oral inflammation in stem cell transplant patients
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autologous Stem Cell Transplant; Chemotherapy; Cryotherapy; Hematological Cancer; Melphalan; Oral Mucositis; Palifermin; Quality Of Life; Randomized Controlled Trial
Abstract
A common treatment option for patients with cancers such as multiple myeloma and lymphoma is taking high-dose chemotherapy drugs followed by a stem cell transplant. However, some high-dose chemotherapy drugs, melphalan in particular, commonly cause severe side effects in patients. Mouth and throat inflammation and ulceration, called oral mucositis, is one of the most debilitating side effects; it can make eating and drinking extremely painful, patients are much more susceptible to infections and patients may need to be hospitalized for several weeks. Finding the best methods to help reduce the occurrence of oral mucositis will be beneficial for patients and for the healthcare system. Current treatment methods include giving patients a drug called palifermin intravenously before melphalan treatment or having patients place ice chips in their mouth before, during and after melphalan treatment. A small number of randomized controlled trials (RCTs) have compared these methods to placebo groups and found that the intervention, whether palifermin or ice chips, was more effective than the placebo under various specific conditions. However, to date, no RCT has compared palifermin to ice chips directly under equivalent and optimized conditions. Therefore, the current study aims to determine which treatment has greater ability to prevent incidence and duration of severe OM (grade 3 and 4 on the World Health Organization Oral Toxicity Scale) in stem cell transplant cancer patients undergoing melphalan chemotherapy. A total of 50 patients aged 18 or older of this described patient population will be randomized to receive either palifermin (25 patients) or ice chips (25 patients). In the palifermin group, patients will be administered the drug intravenously on the 3 days prior to melphalan treatment. In the ice chips group, patients will place ice chips in their mouth for 30 minutes prior to melphalan treatment and will continue until 2 hours after infusion. A trained assistant will physically examine and rate each patient’s mouth based on the Oral Toxicity Scale daily following intervention until patients are free of OM. Once measurements are complete, the proportion of patients with severe OM and the duration of severe OM will be calculated and compared between the groups. The ultimate goals will be to determine which intervention is more effective in reducing the incidence and duration of OM. The result of this study may have important implications for improving stem cell transplant patient quality of life and for optimizing healthcare expenditure.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Suppiah, Roopa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~